4月20日 - ** 药物开发商Celldex Therapeutics CLDX.O股价盘前攀升4%至35.95美元
** 巴克莱（Barclays）将该股评级从 "减持 "上调至 "增持"；将目标价从24美元上调至45美元
** 新的PT较上一交易日收盘价上涨30.2%
** 券商称，该公司药物巴珠单抗的临床试验比原定计划提前六个月完成患者招募，"这至少说明了对该药物的需求和热情"。
** 巴珠单抗 正被开发用于治疗慢性自发性荨麻疹(CSU)，这是一种引起慢性荨麻疹的皮肤病。
** 巴克莱银行（Barclays）将巴珠单抗的成功概率从65%提高到85%，并预计其峰值销售额将达到14亿美元，相关疾病的扩展适应症可能带来更多收入。
** 截至上次收盘，CLDX 年累计上涨 27.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.